Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

Nucala (mepolizumab) and Dupixent (dupilumab) are prescription drugs used to treat chronic rhinosinusitis with nasal polyps, asthma, and COPD. Both drugs come as a liquid solution for injection under ...

Dupixent works by blocking two proteins in your body called IL-4 and IL-13 (interleukins). These are a specific type of protein that can trigger the immune system to respond as if there’s danger when ...

Ebglyss and Dupixent are used to treat moderate to severe atopic dermatitis in certain children. Dupixent is used in children ages 6 months and older. Ebglyss is used in children ages 12 years and ...

Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...